[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576351":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":43,"collaborators":46,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"OHSU Knight Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients may receive up to 3 doses of pneumococcal and\u002For tetanus vaccine per institutional policy of revaccination. Patients undergo blood sample collection and have medical records reviewed throughout the study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":5,"role":22},"Amrita Desai","PRINCIPAL_INVESTIGATOR",[24],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Portland","Oregon","97239","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-122.67621,45.52345,{"lat":35,"lon":34},[38,42],{"name":21,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","503-494-8534","desaia@ohsu.edu",{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":22,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Amrita Desai, M.D.","Principal Investigator",[47],{"name":48,"class":6},"Oregon Health and Science University","100576351","vaccine-responses-in-patient-with-multiple-myeloma-and-non-hodgkin-lymphoma-after-car-t-treatment-100576351",false,"NCT06784167","Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment","Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment","Inclusion Criteria:\n\n* \\* Willingness to provide written informed consent before any study-specific procedures or activities are performed\n\n  * Age ≥ 18 years of age, at the time of consent\n  * Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed\n  * History of prior vaccination against common VPD\n  * Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days\n  * Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus\n\nExclusion Criteria:\n\n* \\* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints\n\n  * Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or make the study procedures unadvisable","ALL","18 Years",{"count":59,"type":60},45,"ESTIMATED","OBSERVATIONAL","This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.",[64,65,66,67,68,69,70],"Chronic Lymphocytic Leukemia","Diffuse Large B-Cell Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Multiple Myeloma","Primary Mediastinal Large B-Cell Lymphoma","Small Lymphocytic Lymphoma","2025-09-08",{"date":73,"type":74},"2025-09-15","ACTUAL",{"date":76,"type":74},"2025-03-10",{"date":78,"type":60},"2027-04-12",{"name":5,"class":6},1]